Spinal Cord Injury Neuroprotection With Glyburide

Inclusion Criteria

• No life threatening injuries resulting from the traumatic accident
• No evidence of sepsis
• Acute cervical or thoracic SCI with ASIA Impairment Scale Grade A, B, or C od admission.
• Non-penetrating SCI at neurologic level from C2 to C8 or T1 to T12

Exclusion Criteria

• Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours
• Acute SCI with ASIA Impairment Scale grade D or E
• Currently involved in another non-observational SCI research study or receiving another investigational drug
• History of hypersensitivity to sulfonylureas, in particular glyburide, or any of its components
• Any condition likely to result in the patient's death within the next 12 months
• Severe renal disorder from the patient's history (e.g. dialysis) or baseline eGFR of \< 30 mL/min/1.73 m2
• Known severe liver disease, or ALT > 3 times upper limit of normal or bilirubin
• Blood glucose \<55 mg/dL at enrollment or immediately prior to administration of DiaBeta, or a clinically significant history of hypoglycemia
• Acute ST elevation myocardial infarction, and/or acute decompensated heart failure, and/or QTc > 520 ms, and/or known history of cardiac arrest (PEA, VT, VF, asystole), and/or admission for an acute coronary syndrome, myocardial infarction, or coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months
• Known G6PD enzyme deficiency